Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience

The international Linked Clinical Trials (iLCT) program for Parkinson’s to date represents one of the most comprehensive drug repurposing programs focused on one disease. Since initial planning in 2010, it has rapidly grown – giving rise to seven completed, and 15 ongoing, clinical trials of 16 agen...

Descripción completa

Detalles Bibliográficos
Autores principales: Stott, Simon R. W., Wyse, Richard K., Brundin, Patrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017145/
https://www.ncbi.nlm.nih.gov/pubmed/33815053
http://dx.doi.org/10.3389/fnins.2021.653377
_version_ 1783674000176578560
author Stott, Simon R. W.
Wyse, Richard K.
Brundin, Patrik
author_facet Stott, Simon R. W.
Wyse, Richard K.
Brundin, Patrik
author_sort Stott, Simon R. W.
collection PubMed
description The international Linked Clinical Trials (iLCT) program for Parkinson’s to date represents one of the most comprehensive drug repurposing programs focused on one disease. Since initial planning in 2010, it has rapidly grown – giving rise to seven completed, and 15 ongoing, clinical trials of 16 agents each aimed at delivering disease modification in Parkinson’s disease (PD). In this review, we will provide an overview of the history, structure, process, and progress of the program. We will also present some examples of agents that have been selected and prioritized by the program and subsequently evaluated in clinical trials. Our goal with this review is to provide a template that can be considered across other therapeutic areas.
format Online
Article
Text
id pubmed-8017145
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80171452021-04-03 Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience Stott, Simon R. W. Wyse, Richard K. Brundin, Patrik Front Neurosci Neuroscience The international Linked Clinical Trials (iLCT) program for Parkinson’s to date represents one of the most comprehensive drug repurposing programs focused on one disease. Since initial planning in 2010, it has rapidly grown – giving rise to seven completed, and 15 ongoing, clinical trials of 16 agents each aimed at delivering disease modification in Parkinson’s disease (PD). In this review, we will provide an overview of the history, structure, process, and progress of the program. We will also present some examples of agents that have been selected and prioritized by the program and subsequently evaluated in clinical trials. Our goal with this review is to provide a template that can be considered across other therapeutic areas. Frontiers Media S.A. 2021-03-19 /pmc/articles/PMC8017145/ /pubmed/33815053 http://dx.doi.org/10.3389/fnins.2021.653377 Text en Copyright © 2021 Stott, Wyse and Brundin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Stott, Simon R. W.
Wyse, Richard K.
Brundin, Patrik
Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
title Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
title_full Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
title_fullStr Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
title_full_unstemmed Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
title_short Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
title_sort drug repurposing for parkinson’s disease: the international linked clinical trials experience
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017145/
https://www.ncbi.nlm.nih.gov/pubmed/33815053
http://dx.doi.org/10.3389/fnins.2021.653377
work_keys_str_mv AT stottsimonrw drugrepurposingforparkinsonsdiseasetheinternationallinkedclinicaltrialsexperience
AT wyserichardk drugrepurposingforparkinsonsdiseasetheinternationallinkedclinicaltrialsexperience
AT brundinpatrik drugrepurposingforparkinsonsdiseasetheinternationallinkedclinicaltrialsexperience

Ejemplares similares